List of Biotech, Pharmaceutical & Life Sciences companies in Ireland - 65

Alkermes seeks to develop innovative medicines that help address the unmet needs and challenges of people living with debilitating diseases. As a fully-integrated, global biopharmaceutical company, Alkermes applies its scientific expertise, proprietary technologies and global resources to develop products that are designed to make a meaningful difference in the way patients manage their disease.

At Altratech, we are moving serology and the monitoring of viral contagious diseases out of the laboratory to the point-of-care and community clinics. We are a team of twenty scientists and engineers, including nine PhDs, from cross-functional backgrounds of molecular biology, organic and synthetic chemistry, microfluidics, engineering and CMOS semiconductor technologies. With over 200 years of combined experience, our vision is to create portable high-performance diagnostics which will enable the next generation of decentralised connected healthcare and wellbeing.

Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. We are committed to increasing the scientific understanding of the cardiovascular risk that persists beyond traditional therapies and advancing the treatment of that risk for patients worldwide. Amarin has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, Zug in Switzerland, and other countries in Europe as well as commercial partners and suppliers around the world. For more information, visit www.amarincorp.com. See our Community Guidelines: bit.ly/2L7xEW6

Amryt Pharma was acquired by Chiesi Farmaceutici S.p.A. (“Chiesi”) April 12, 2023. Amryt is a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases.

AnaBio Technologies is a biotechnology company based in Ireland that specializes in microencapsulation technologies. The company enhances the delivery and effectiveness of sensitive bioactive ingredients, focusing on precision nutrition solutions for both human and animal health. Founded by Dr. Sinéad Bleiel, AnaBio originated from her PhD research and has grown to employ around 20–27 staff, generating reported revenue of $6.4 million. AnaBio offers a range of services, including microencapsulation technology that protects ingredients like probiotics and vitamins from degradation. They develop customized formulations for controlled release, optimizing effectiveness in dietary supplements, infant nutrition, and sports recovery. Their flagship product line includes encapsulated probiotics designed to improve gut health outcomes. Additionally, AnaBio is expanding its offerings to include specialized microencapsulated ingredients for livestock and pet health. The company serves global clients across the food, pharmaceutical, and animal nutrition industries, emphasizing scientific innovation and tailored solutions.

Aran Biomedical is now part of Integer. Visit www.integer.net to learn more. Aran Biomedical is a trusted partner in design, development and manufacture of biomaterial focused medical implant products. We provide expertise in medical textiles, biomaterial covering and coating of implants, as well as absorbable implants. We have a proven track record in innovative design and quality-assured manufacturing, delivering solutions for a range of different markets and medical applications. Aran Biomedical enables you to supply next generation products to clinicians and their patients. • Cardiovascular • General Surgery • Orthopaedics Aran Biomedical offers a complete solution to medical device companies who seek a contract partner to help realise their product development needs, from concept to finished packaged medical implants. From concept design and development through to the production transfer of approved medical devices in a quality assured environment, Aran Biomedical is committed to providing an unparalleled degree of service. Dedicated consultation, project management, and technical resources are provided throughout to ensure clients' expectations are surpassed in taking quality products to market.

We are a biopharmaceutical company passionately committed to providing solutions for overlooked and unmet medical needs through patient-focused, innovative products.

Avectas is accelerating the future of cell therapy with a flexible, easy-to-integrate delivery platform that manufactures healthier and more functional cells for patients. Excelling at complex editing and challenging cargo delivery, the Avectas non-viral delivery platform ensures the next generation of cell therapies can be realized. The Solupore non-viral delivery system enables the next generation of cell therapies through unparalleled cell health and superior cell functionality, expanding the possibilities for complex editing and challenging cargo delivery. Easy to integrate into existing GMP processes, Solupore accelerates the translation of life-saving therapies to patients.

At Biostór Ireland Ltd, our success is driven by a culture of collaboration, innovation and determination. We believe in progressive thinking, in challenging ourselves and each other, with the goal of enhancing patient outcomes and patient lives. Our mission is to serve our customers with the highest quality, ethics and practices, and to provide best in class customer service & client experience. We are a Bio repository for temperature critical storage of bio materials & a choice of controlled storage conditions down to -196°C (Liquid Nitrogen Vapour) and a range of validated cold-chain distribution services. Biostór is validated to GMP standards. The Quality Management System is designed to comply with applicable EU & US regulations and international standards: ISO 13485:2003. The company has been audited and approved by major US FDA regulated multinational pharmaceutical companies. Our operations are subject to stringent regulation as set down by EU Tissues & Cells Directives. In March 2008 the facility was inspected and accredited by the Irish Medicines Board (IMB) as a Tissue Establishment for the GTP storage and distribution of Human Tissues and Cells for human application throughout the 27 member countries of the EU. Biostór can cater for a wide range of sample types: Active Pharmaceutical Ingredients (APIs) and Finished Products, Clinical Trial Samples, Donor Materials, Plasma, Serum and Body Fluids, Human Tissues and Cell Products i.e., Bone Marrow, Cord Blood & Reproductive Cells. The company currently maintains the national archive of Bone Marrow, Peripheral Stem Cells and Donor Lymphocytes for the country's main cancer hospital. Biostór Ireland is located at Rosslare Harbour, Co. Wexford, 2km from the international Europort with fast road/ferry transit times to UK & Europe, 2 hours by road from Dublin/Cork airports with overnight courier service to all European centres. The store has a current capacity for 5 million biological samples.

Cara Partners is a pharmaceutical manufacturing company that specializes in producing a standardised extract of Ginkgo Biloba, an Active Pharmaceutical Ingredient (API), in County Cork, Ireland.

Carrick Therapeutics is pioneering a portfolio of unique, first in class, cancer treatments that target driver mechanisms of the most aggressive forms of cancer, and which will be tailored to an individual patient’s tumour. Targeting the molecular pathways that drive the most aggressive and resistant forms of cancer will transform the way that cancer is treated and have a major impact on the lives of cancer patients. By linking a network of clinicians and scientists in internationally leading research institutes and hospitals, Carrick will streamline the introduction of these ground-breaking cancer therapies into the clinic, thus serving cancer patients around the world.

Celtic Biotech is developing novel candidate therapies for the treatment of solid cancers and pain in humans. Derived from specialised receptor binding proteins found in snake venom, these product candidates have the potential to increase survival, improve quality-of-life and reduce treatment costs for cancer patients. Celtic Biotech is focusing its research on solid tumours, including non-small-cell lung cancer (NSCLC), as its initial targets. The Company's lead candidate, CB24 (Crotoxin), has been observed to be highly toxic to various tumour cell lines in pre-clinical and early clinical studies.

Consilient Health is a pharmaceutical company with a rich heritage of commercialising medicines in areas including women’s health, urology and endocrinology. Established in 2005, Consilient Health is headquartered in Ireland with offices in the UK and Sweden (for the Nordic region) We have formed strong partnerships in Benelux and Spain and continue to expand our geographic footprint in Europe. As an independent, privately-held and profitable business with a strong balance sheet, we can make decisions quickly and are able to invest in long-term collaborations and partnerships to expand our portfolio of products and to support our partners’ objectives. Our goal is to address patients’ and healthcare professionals’ unmet needs with medicines that are differentiated and we are actively seeking to in-license late stage developments or marketed products. We do not undertake research and development and are not a manufacturer. Consilient Health deliver everything from regulatory affairs through to market access, supply chain, distribution, medical affairs, marketing and sales all underpinned by quality and compliance. Our focus is on driving value in our partners’ brands, maximizing their commercial potential, enabling them to expand their geographical footprint and providing access for patients. For more information please visit www.consilienthealth.com CORP-CH-204(2) Date of preparation July 2022

Cosmo Pharmaceuticals improve people's lives by developing innovative treatments that address significant unmet clinical needs and improve clinical outcomes in the field of gastroenterology and endoscopy. Our clinical development pipeline specifically addresses innovative treatments for gastro-intestinal diseases and Colon Infections. Our effort is aimed to reduce the incidence of Colorectal Cancer (CRC) by increasing the detection rate of pre-cancerous lesions during colonoscopy. Along with our presence in drugs manufacturing, we have significant innovative research and operations supporting our growing portfolio of specialty products. Learn more at www.cosmopharma.com/.

What We Do CyGenica uses a non-viral, non-toxic platform to develop in vitro and in vivo delivery solutions for drugs, gene editing components, and antibiotics. The most crucial issue of intracellular delivery for large molecules, especially for gene therapy, remains the cellular membrane. This biological barrier is a double-edged sword; while it prevents infectious agents from entering our body and causing disease, it also stands between the successful use of life-saving medicines and advanced therapeutic technologies. The successful delivery of therapeutics into target cells and organelles would minimize the undesired ‘off target' side effects and reduce the required dose. Why We Do Our founder's father was diagnosed with cancer when she was still a student. She witnessed her father suffering from the side effects of his therapy over years. This life experience defined the goal of her life 'how to make cancer drugs safer and better' to make an impact in oncology and do her bit in the global fight against cancer. CyGenica is the result of her and our team's intense desire to make significant contributions to alleviate this suffering and improve the quality of life of millions of cancer patients. Who We Are We are a team of ambitious academicians and professionals striving to improve patient outcomes worldwide. Our goal is to develop the world's safest molecular carrier for therapeutics delivery and grow as an authentic market leader in enabling the next generation genome editing therapeutics for various life-threatening diseases such as cancer. With an indomitable spirit, we are committed to improve the quality of life of such patients.

Deciphex is building a global network of AI empowered pathologists, ensuring accessible, innovative pathology services that improve patient outcomes. The pathology industry is beset with increasing caseload and diagnostic complexity, against a globally declining number of pathologists to service the workload. We believe that digital pathology combined with computer aided diagnostic tools will help make pathologists work more efficiently in the future, and offers a solution to the pending crisis in supply/demand in pathology services.

At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world’s leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX – The Diagnostic Network®. DXRX is the world’s first diagnostic commercialization platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.

DS Biopharma was established to discover and develop scientifically innovative healthcare solutions that improve the quality of life for people with diseases for which current therapies are unsatisfactory. Our vision is to enhance people's dignity and well-being by developing these products through a careful balance of applied pharmacology and clinical science.

We are a research-driven company that specialises in the development, manufacture and supply of a broad range of High Potency Oral Solid Dose (OSD) Human & Veterinary speciality products. Since 2006, we have built a reputation as an innovative company specialising in developing and manufacturing of film-coated tablets, soft-gel capsules, and powder or liquid-filled hard-shell capsules. Our work, which focused on successfully producing cancer chemotherapy drugs, allowed us to create strong partnerships with leading pharmaceutical companies, thus making our founders' vision a reality. In 2015, our successful track record and reputation for industry excellence prompted the acquisition of Eirgen Pharma by the OPKO Health family of companies. Becoming a part of OPKO Health has allowed Eirgen Pharma to invest further in our facilities and our people, increasing development and manufacturing capabilities. Eirgen now serves patients in more than 60 countries worldwide, including major markets such as the USA, Europe, Japan, Canada, Australia, the Middle East and Africa. Nowadays, at Eirgen Pharma's centre of excellence in Waterford, Ireland, we simplify the journey of getting your product to market by providing full turnkey CDMO services for the development, manufacture and packaging of high potency oral dose medicines for both human and veterinary use. Eirgen also holds the production rights for numerous OSD products and has the capacity to manufacture each of these products at scale.

ERS Genomics was formed to commercialise the foundational CRISPR-Cas9 intellectual property held by co-inventor, co-owner and Nobel Prize-winner Dr. Emmanuelle Charpentier. Licenses are available in multiple fields of use. CRISPR-Cas9 is a revolutionary new genome editing technology, which offers significant advantages in speed, efficiency and cost over earlier genome editing methods. Our team has decades of experience in the field of genome editing and its application, in business development and licensing, licensing preclinical and clinical stage therapeutic products and drug delivery technologies, genome editing technologies as well as overseeing research and development. To learn more about acquiring your license, contact us today.

FIRE1 aims to improve patient quality of life, and patient outcomes, while lowering overall healthcare costs.

Galactica Biotech provides a drug repurposing method to identify novel applications for molecules in the market and in development for major and orphan diseases, reducing risk for patients and time and cost for companies. Our Mission With our specialized knowledge we are targeting to set new standards in the pharmaceutical industry adding value to old drugs and contributing to the health of people.

GenoME Diagnostics is a spinout from the prestigious Patrick G Johnston Centre for Cancer Research at Queen's University Belfast. We are developing novel blood tests for earlier and more accurate detection of ovarian and pancreatic cancers. GenoME Diagnostics aims to reduce the misdiagnosis and late detection to improve patient survival and outcome. Our pipeline could be applied to biomarker discovery and development in a wide range of diseases and applications.

GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that is being investigated in the Phase 2 part of an ongoing Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate that is in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was founded in 2018 and is based in Dublin, Ireland.

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with Lupus Research and HemoShear Therapeutics, LLC. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland with additional offices in Deerfield, Illinois; Chicago, Illinois; South San Francisco, California; Washington, D.C.; Gaithersburg, Maryland; Rockville, Maryland; and Mannheim, Germany.

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was founded in 2015 and is headquartered in Dublin, Ireland.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ), is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are focused on developing life-changing medicines for people with serious diseases—often with limited or no options—so they can live their lives more fully. By transforming biopharmaceutical discoveries into novel medicines, we are working to give people around the world the opportunity to redefine what’s possible – to make the “small wins” big again. Founded in 2003 and headquartered in Dublin, Ireland, Jazz Pharmaceuticals has a significant corporate presence in Palo Alto, CA and Philadelphia, PA and in England in London, Oxford and Cambridge, with manufacturing facilities in Ireland, England and Italy. We maintain a highly collaborative culture where employees focus on how they can be successful and accomplish positive results by exemplifying the company’s core values: integrity, collaboration, passion, innovation and the pursuit of excellence. Together, we are experts, analysts, specialists, advocates, scientists and professionals all with diverse backgrounds and perspectives. Working together, we are proud to support patients, innovate and bring new medicines to patients with critical unmet needs. Please see our website at www.jazzpharma.com for more information. For information on recruitment, please visit https://careers.jazzpharma.com/. For guidelines on engaging with Jazz on social media, please visit https://bit.ly/2OaMOuq.

Juvenescence is a life sciences company developing therapies to modify aging and increase healthy human lifespan. The Juvenescence team consists of highly experienced drug developers, entrepreneurs, marketers, and investors with a significant history of success in pharmaceutical drug development, synthetic biology, and tissue and cellular engineering. Juvenescence has a broad pipeline in development and is driving innovation, with a focus on discovering and developing these therapies to modify the aging process, through prevention and by regenerating damage, to support healthy aging and increase health span.

Keltic Pharma is based in a world leading laboratory in Glasgow with our highly skilled team of industrial scientists and leading academics. We work alongside commercial partners and universities to deploy novel innovative technologies in the pursuit of next generation drugs for unmet clinical needs.

Loci Orthopaedics develops innovative orthopaedics medical technologies to meet large unmet clinical needs.

Luminate Medical is a healthcare technology company that builds devices to make cancer care better for patients by preventing side effects and making at-home treatments a possibility. Based in Galway, Ireland, Luminate is pioneering the development of Lily, a device to prevent chemotherapy induced hair loss in a comfortable and portable way, Lilac, the world's first preventative treatment for peripheral neuropathy, and further pipeline projects enabling remote cancer care. Luminate is a VC-backed startup funded by Y Combinator (S21) with multiple successful grant and investment rounds to date.

Metabolomic Diagnostics is a deep-tech company specialised in the development of novel biomarker based diagnostic solutions for complex diseases. The company has developed an effective pipeline to firstly identify diagnostic biomarker panels and then translate these panels into clinical assays ready for application in the clinical laboratory. Metabolomic Diagnostics’ primary vision is to develop a portfolio of diagnostic solutions which can determine, early in a woman’s pregnancy, her risk of developing major complications much later in her pregnancy and thus enabling personalized care, adapted to each woman’s individual needs. Pregnancy complications like preeclampsia, gestational diabetes, preterm birth, and in-uterine growth restriction, all have the potential to severely impact on the well-being of mother and child.

For over 130 years, MSD has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases in pursuit of our mission to save and improve lives. MSD is a trade name of Merck & Co., Inc., with headquarters in Kenilworth, N.J., U.S.A. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, MSD continues to be at the forefront of research to prevent and treat diseases that threaten people and animals — including cancer, infectious diseases such as HIV and Ebola, emerging animal diseases, and, most recently, Covid-19 — as we aspire to be the premier research-intensive biopharmaceutical company in the world. For more information, visit www.msd-ireland.com

For over 130 years, MSD has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases in pursuit of our mission to save and improve lives. MSD is a trade name of Merck & Co., Inc., with headquarters in Kenilworth, N.J., U.S.A. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, MSD continues to be at the forefront of research to prevent and treat diseases that threaten people and animals — including cancer, infectious diseases such as HIV and Ebola, emerging animal diseases, and, most recently, Covid-19 — as we aspire to be the premier research-intensive biopharmaceutical company in the world. For more information, visit www.msd-ireland.com

Established in 2009, MyBio is a premium supplier of research products, technology, and expertise. We're at the forefront of innovation, enabling the science that's changing lives for the better. Our clients include a range of life scientists based in research laboratories from a variety of sectors. For Academia As scientists ourselves, we understand the challenges that are faced by researchers every day. From needing that all important reagent as quickly as possible, to having to keep an eye on budget – we can help every step of the way too. Quality & Support Our partners are carefully selected, meaning that the products they produce are of the highest quality. As scientists, we only supply tools and equipment that we would use ourselves. Time is of the essence for a busy researcher, therefore we offer full troubleshooting support for when things are not quite going to plan. For Pharma We are an established supplier of custom products for the pharmaceutical industry, with a team of dedicated scientists experienced in the drug discovery and development process. Using our expertise, we are able to work closely with pharmaceutical companies confidentially, tailoring solutions to their unique problems through our well-established ties with our suppliers. We are able to provide our clients with truly customized products that allow for the efficient conversion of potential API leads into candidates and through to established therapeutic drugs. For Suppliers We are always looking to evolve alongside new partners, and have a proud record of delivering strong growth for our suppliers, owing to our knowledge of our customers’ challenges, and our experience of the market on a national level. MyBio are innovative and ambitious, and we are proud of our reputation as one of Ireland’s most trusted suppliers, helping manufacturers penetrate the market and deliver their trusted innovations to laboratories nationwide.

Neuromod is a medical device company formed to advance the science of bi-modal neuromodulation. We are committed to delivering treatments that significantly reduce the suffering of underserved patient populations who live with chronic and debilitating conditions globally. Our goal is to design products that empower patients to take control of their own treatment, delivering targeted therapies that integrate seamlessly into a modern lifestyle. Neuromod has developed and patented a bi-modal neuromodulation technology that it is evaluating for neurological disorders including chronic tinnitus, a condition affecting 10% of the adult population and commonly known as 'ringing in the ears'​.

When a patient is critically ill, giving their doctor the right information at the right time can mean the difference between life and death. At Novus Diagnostics, we are developing ground-breaking diagnostics technologies to provide rapid answers right at the patient’s bedside. Our first product, SepTec, will help tackle the global challenge of sepsis which kills more than 11 million people every year. Our technology platform brings together novel electrochemical sensors, centrifugal microfluidics and automated sample processing and analysis to diagnose and characterise a blood stream infection within 15 minutes; enabling earlier lifesaving targeted treatment. We are a young, driven company working to solve a major global health challenge. We are building a team of people who are excited by this challenge and committed to making a real difference through their work.

A multi-award winning Irish company innovating in women's health. Nua Surgical was developed out of BioInnovate Ireland and is dedicated to innovating in Women's Health. The team are currently pursuing solutions to unmet clinical needs in obstetric surgery. In 2018, the founding team secured a 2 year Research and Commercialisation Grant from Enterprise Ireland to develop the SteriCISION C-Section Retractor at the University of Galway. Brief Overview of Achievements: 𝟮𝟬𝟭𝟴 - Our founding team were awarded an Enterprise Ireland Commercialisation Fund to bring the project from early stage concept to commercialisation.  This was based at the University of Galway. 𝟮𝟬𝟭𝟵 - Nua Surgical was chosen as one of seven start-ups between Ireland and the U.S. to participate in the Blackstone-backed accelerator 'LaunchPad Lift' powered by Techstars. - Our CEO was named 'Best Senior Entrepreneur' at the EIT Health Alumni Needs-Led Innovation Showcase in Lisbon, Portugal. 𝟮𝟬𝟮𝟬 - One of 16 UK and Ireland Start-ups to be awarded €40,000 through the EIT Health Headstart Programme. - One of 15 winners for the national HIHI Healthcare Innovation Call 2020.   - Winner of the InterTrade Ireland Seedcorn Competition, securing €100,000.   𝟮𝟬𝟮𝟭 - Winners of the Global Healthy Mom and Baby Innovation Competition 2.0, run by Parkview Health and MATTER (USA).  𝟮𝟬𝟮𝟮 - Won MedTech category of the 'Global Tech For Good' Competition run by Empact Ventures, Hays and the NIHR. - Winner of the MedTech Category at the National Start-Up Awards, followed by overall Grand-Prix Winner at the famous Dublin City Hall ceremony.  𝟮𝟬𝟮𝟯 - The only non-US company to participate in Cohort 15 of the prestigious Texas Medical Center HealthTech Accelerator. - 1 of 8 Irish finalists for the KPMG Global Tech Innovation Awards. - 'Emerging MedTech Company of the Year' at the prestigious Irish MedTech Awards. - Double winners at the 2023 National HealthTech Innovation Awards.

Omnispirant is a biotechnology company that develops a novel platform technology using inhaled stem cell exosomes for treating respiratory diseases.

OncoAssure is a medical diagnostics company that identifies, develops, and commercialises clinically important biomarkers to significantly improve cancer management and treatment. We aim to help clinicians provide the right treatment to the right patient at the right time.

ONK Therapeutics, is an innovative cell therapy company dedicated to developing a next generation of off-the-shelf, dual-targeted NK cell therapy platform targeting hematological malignancies and solid tumors. The Company was founded in 2015, by Prof. O’Dwyer MD, of NUI Galway, an expert in translational multiple myeloma research, the tumour microenvironment, and exploitation of NK cells as cellular immunotherapy. Its core proprietary platform is based on a dual-targeted NK cell expressing both a chimeric antigen receptor (CAR) targeting a known tumour antigen and a TNF related apoptosis inducing ligand variant (TRAILv) targeting the death receptor pathway (i.e. DR4 or DR5). This promising new approach has the potential to enhance efficacy by addressing both intrinsic (e.g. CAR engagement of a tumor specific antigen) and extrinsic (e.g. signalling through the death receptor pathway) apoptotic pathways, and to reduce the susceptibility to possible target antigen escape through the engagement of tumor antigen independent TRAILv.

Orbsen Therapeutics Limited aims to become a leading company in the development of regenerative medicine therapies across a range of diseases and medical conditions. We are developing a novel proprietary technology that permits the isolation of pure and defined stomal cells from human tissue and a range of other species. The multi-species elements allow our technology to move seamlessly from the research laboratories to the clinic. The technology is designed to ensure that resulting therapies comply with the forthcoming stringent EMA and UK BSI guidelines regarding the purity and definition of cellular therapies. We believe that our technology will set the standard for regenerative medicine into the future. Orbsen Therapeutics was originally formed in 2006 as a spin out company from REMEDI, Ireland's Regenerative Medicine Institute in NUI Galway. Founded and led by some of the leading scientists in the field of regenerative medicine we operate from within the Orbsen Building, on campus at NUI Galway, which houses REMEDI's state of the art research facilities. The company has already participated in EU FP7 funded research progammes and has a significant research pipeline coming to fruition over the coming years.

Ovoca Bio is a clinical-stage biopharmaceutical company with a focus on women’s health. The Company is currently developing a novel treatment for women with hypoactive sexual desire disorder (HSDD), a condition characterized by a distressing lack or loss of sexual desire. The Society for Women’s Health Research estimates that about one in ten premenopausal women suffer from HSDD, making it one of the most common female sexual problems.

Developing innovative catheter technology to treat acute ischemic stroke, providing superior clinical outcomes in shorter procedural times.

PLANTeDIT uses genome editing tools such as CRISPR/Cas9 RNPs® to create genome edited plants.

Prothena is a late-stage clinical biotechnology company with expertise in protein dysregulation and a diverse pipeline of novel investigational therapies for neurodegenerative and rare peripheral amyloid diseases. We are committed to developing novel and transformative medicines to create a better future for people in critical need of new treatment options. Our product portfolio is designed to make a significant impact on neurodegenerative and rare peripheral amyloid diseases, which affect millions of people and their families worldwide. We leverage insights around neurological dysfunction and the biology of misfolded proteins to develop novel therapeutic solutions that directly target pathogenic proteins in order to change the course of devastating diseases. At Prothena, our success is driven by our people. We are dedicated to attracting individuals who share our vision to improve human health by putting patients first. Our shared humanity drives a passionate and unwavering commitment to apply high scientific rigor toward developing innovative new therapies for patients. We have ambitious goals and take every aspect of our mission seriously, while enjoying the journey. Our values connect us – you will see and feel them come to life in all we do – together.

ProVerum Medical is a Dublin-based medical device company founded in 2016. The company specializes in minimally invasive solutions for benign prostatic hyperplasia (BPH), focusing on developing technologies that address lower urinary tract symptoms caused by prostate enlargement. Their primary product, the ProVee System, features a nitinol expander designed to reshape the enlarged prostate and alleviate urinary obstruction. This system is deployed through a low-profile, flexible delivery method that integrates imaging, making it compatible with standard office-based endoscopes. The procedure is minimally invasive and can be performed under local anesthesia, offering a patient-friendly alternative to traditional surgery. ProVerum holds eight patents, including one granted in 2023 for a device that deploys expandable implants targeting BPH and urinary system disorders. The company has raised a total of $38.58 million in funding, including a €30 million Series A round in 2022. ProVerum is currently conducting the ProVIDE study to evaluate the safety and efficacy of the ProVee system, which completed enrollment in March 2024.

SOSV is a global venture capital firm that operates early stage startup development programs. SOSV’s programs are focused on revolutionary deep technology that promises the betterment of humanity and the planet. The firm’s strategy is to invest in a small number of highly promising startups and use its deeply resourced programs to accelerate product development, acquire customers, and scale. SOSV companies consistently raise funding rounds led by top tier investors. SOSV joins seed, Series A, and later rounds while providing founders with ongoing support and community. As of January 2024, SOSV had more than 1,000 portfolio companies and $1.5 billion in assets under management. SOSV’s programs include hard tech-oriented HAX and life-science driven IndieBio. Both offer deep technical and scientific expertise on-site as well as well-equipped lab and fabrication facilities and supply chain access. Among the top companies in SOSV’s portfolio are NotCo, Upside Foods, Unspun, Opentrons, Mycoworks, and Prime Roots. SOSV releases the annual Human Health 100, a list of the firm’s top human health investments in areas ranging from assistive robotics to therapeutics and diagnostics. SOSV also publishes the annual Climate Tech 100, a list of the firm’s top climate-focused investments working on solutions to climate change across five sectors: food, manufacturing, transport, energy, and building systems.

Relevium Medical are a biopharmaceutical company with locations in Ireland and the US. We aspire to improve the lives of people with debilitating chronic pain conditions through creating superior treatments.

Renexxion Ireland Innovation There is a large unmet medical need for patients with disorders of gastrointestinal motility. Naronapride, a late-development stage, Phase-3 ready, oral gastro-prokinetic, 5-HT4 agonist has shown efficacy in a wide range of these disorders. It is estimated that at least 16% of people worldwide suffer from GI-related disorders. Currently approved therapies do not completely address this high therapeutic need. In some cases, there are no approved therapies. Naronapride has the potential to address the major GI indications associated with dysmotility including chronic idiopathic constipation (CIC), irritable bowel syndrome - constipation type (IBSc), functional dyspepsia (FD), gastroparesis (GP), and gastro-esophageal reflux disease (GERD), in particular PPI-resistant GERD where chronic oral treatments are required. Naronapride may also address unmet therapeutic needs in smaller GI-related indications, both chronic and acute. These include Enteral Feeding Intolerance (EFI), acute GP, short bowel syndrome (SBS), and post-operative ileus (POI).

Rockfield Medical Devices is an innovative SME developing feed delivery systems which will transform the mobility and quality of life of those on tube feeding.

SeqBiome is a world leading microbiome contract research company, providing first in class technical and scientific services to researchers in leading companies in the Pharma, Food, and Nutrition industries and to academic researchers in top Universities. SeqBiome measures, analyzes, and interprets the microbiome using state-of-the-art tools, partnering with industry and academia to offer custom sequencing and bioinformatics services. We are committed to helping our customers derive actionable insights from their projects. SeqBiome offers an end-to-end Microbiome analysis service for our customers. We add most value to our customers by being involved early in their study and we can assist them with Statistical Study Design, Sample Processing, Metagenomic Sequencing, Compositional and Functional Microbiome Analysis, Biostatistical and Bioinformatic Analysis, and Publication/Patent Ready Outputs.

Serosep are Ireland's leading Microbiology Diagnostics specialists. We are proud of our position as the innovative, specialist partner of choice for customers in Ireland, the UK, the European and world markets. Our loyal customer network of individuals & Laboratory's enjoy and depend on the many benefits of our easy to use Diagnostic product line. For over 20 years we have built a strong competitive position based on responsive customer service, laboratory operations and diagnostics knowledge with a committed and specialist team. We are committed to continuously improving our own operations, the design of our diagnostic products and the standards of best practice in our activities across the markets in which we supply and service.

At Shorla Oncology we develop and commercialize innovative oncology drugs for women's and pediatric cancers. We focus on indications where existing treatments are limited, in shortage or inadequate for the target population. Our products are the result of Shorla's world class team encompassing thought leaders, clinicians, scientists and commercial strategists who have extensive experience in the area of drug development and commercialization of niche cancer treatments. Our growing portfolio will bring accessible, affordable and life-saving treatments to patients, delivering a major contribution to patient care and providing a significant clinical impact.

SOMAÍ Pharmaceuticals is a leading EU-GMP European vertically integrated Multi-Country Operator (MCO) company with a global footprint of distribution for the largest and most advanced EU GMP-certified cannabinoid-containing pharmaceutical extract portfolio. At SOMAÍ, we are building a leading global brand with the most robust pipeline of innovative cannabis-based therapeutics. We envision a world where people live a healthy lifestyle empowered by natural cannabis medicine. SOMAÍ owns a state-of-the-art manufacturing facility and indoor cultivation in Lisbon, Portugal, and has global sales teams in the largest medical cannabis markets. We are continuing to make acquisitions and global brand partnerships that make us one of a few and the first European-based vertically integrated companies in the EU able to cater to the diverse needs of fast-growing global cannabis markets.

South East Technological University is a higher education institution in the South East region that focuses on technology, research, and innovation.

Spinal Stabilization Technologies, LTD ("SST") is a commercial-ready U.S. medical device company with a manufacturing facility in Ireland through its Irish subsidiary. The Company has developed a new surgical device and procedure for restoring the nucleus pulposus of the lumbar spine. The company has extensive worldwide intellectual property. The products and techniques SST develops are based on the philosophy that less invasive surgery may be associated with better clinical outcomes. These products and techniques could improve the lives of many patients that have limited options for treating their back pain. The company is focused on evidence-based medicine, has completed three trials, is currently conducting a clinical trial and is in the planning phase of two additional clinical trials.

Our team at Starling Surgical is working to develop a new revolution in wound closure technology. The Quickstitch is the only device that provides all the clinical advantages of meticulously tied sutures, at the speed of a skin stapler. Our goal is to disrupt the industry of wound closure by delivering a device that provides an optimum wound closure every-time. The device is so intuitive to operate, that users have been delighted by its simplicity. Whether it is a long arduous coronary artery bypass or a short quick mole removal, the only part the patient sees, is the scar. We want to make sure your patients see a beautiful scar after every operation. Our team has developed, tested, iterated and developed and tested some more, to give you the best device for wound closure. Our goal is to get the QuickStitch into the hands of users, so they can see the amazing results for themselves.

SynOx Therapeutics Ltd was founded in November 2020 and is solely focused on developing emactuzumab for the treatment of diffuse tenosynovial giant cell tumours (TGCT) and other indications. SynOx is backed by a strong investor syndicate with long and successful backgrounds in building biopharma companies.

Trinity Biotech specialises in the development, manufacture and marketing of diagnostic test kits and equipment. The quality and efficacy of our products is essential to ensure clinicians and patients are provided with a reliable, safe and robust method of diagnosis. It’s essential that we are always cognisant that a patient may receive a life changing diagnosis from one of our products. Trinity Biotech is a company which is made up of a wide range of people from different backgrounds and experience. Our goal is to have a friendly, inclusive and fun place to work which also supports the needs of our business. Working at Trinity Biotech means working on a range of items which provides great experience and keeps our roles interesting, challenging and rewarding. Our size makes us an organisation which is large enough to ensure there is a wide range of activities, projects and day to day variety.

Ulysses Neuroscience Limited is an Irish Private R&D Organisation providing clinical and preclinical research services to pharmaceutical companies.

Uniphar is a diversified healthcare services organisation with activities in Ireland, UK, Europe, the USA and APAC.

Utah Medical Products, Inc., with particular interest in health care for women and their babies, develops, manufactures and markets a broad range of disposable and reusable specialty medical devices recognized by clinicians in hundreds of countries around the world as the standard for obtaining optimal long term outcomes for their patients. For more information about Utah Medical Products, Inc., visit UTMD’s website at www.utahmed.com.

The company develops advanced polymer implants and delivery systems, primarily focused on minimally invasive vessel closure in cardiology, interventional radiology and vascular surgery.

Today one of Europe’s premier facilities, Weatherbys Scientific in Ireland has been involved in animal parentage testing since 1985. The laboratory has been accredited with CSPro certification by Illumina, has ISO 17025 certification and is also accredited by The International Committee for Animal Recording (ICAR). We are continuously expanding our range of services to match the needs of the industry. Initially the laboratory offered a blood typing service to confirm pedigrees, as part of foal registration. Then, in 1990, the laboratory extended this to the non-thoroughbred sector as part of the registration of foals for the Irish Horse Board. The laboratory introduced DNA technology at the beginning of this century. This superseded blood-typing and provided further opportunities to confirm pedigrees of other animal species such as cattle, sheep, dogs and cats. The Laboratory is now offering its services to the Irish and British livestock industries. It is recognised by the International Society of Animal Genetics (ISAG) as one of the leading laboratories in the world in pedigree verification. It is the only such laboratory in Ireland recognised by ISAG to have achieved the necessary standards in multi-species parentage testing. In January 2011 the laboratory introduced cattle genomic testing. This enhances the prediction values for the estimated breeding index (EBI) of individual breeding stock in the livestock industry. We are now genotyping with the bovine IDB V3, 54K and 770K (HD) SNP chips to increase reliability of genetic predictions in the livestock industry